GlassScriptPhysician profile
Michael Chahin
NPI 1245735661
$5,708.46
in general payments reported to CMS, 2019-2025
49 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $699 · 2023: $1,026 · 2024: $1,392 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.14 |
| Education | $119.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $475.39 | 2022-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $403.01 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $400.26 | 2022-2025 | Calquence, Imfinzi, Lynparza |
| Regeneron Healthcare Solutions, INC. | $288.54 | 2023-2025 | Libtayo |
| Secura Bio, INC. | $259.65 | 2022-2023 | Copiktra |
| Janssen Biotech, INC. | $254.15 | 2024-2025 | Darzalex, Erleada, Balversa |
| Seagen INC. | $248.98 | 2022-2023 | Padcev |
| Novartis Pharmaceuticals Corporation | $229.37 | 2024-2025 | |
| Eusa Pharma (US) LLC | $215.90 | 2021 | |
| Rigel Pharmaceuticals, INC. | $205.76 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pfizer INC. | $186.22 | 2024-2025 | |
| Daiichi Sankyo INC. | $184.69 | 2024-2025 | Enhertu |
| Janssen Scientific Affairs, LLC | $173.48 | 2023 | Darzalex |
| Alexion Pharmaceuticals, INC. | $168.18 | 2023-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $161.25 | 2022-2025 | Xpovio |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $158.27 | 2024-2025 | Reblozyl |
| Gilead Sciences, INC. | $144.95 | 2023-2025 | Trodelvy |
| Morphosys, US INC. | $120.53 | 2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $108.80 | 2023 | Imbruvica |
| Genentech USA, INC. | $105.57 | 2024-2025 | Polivy, Itovebi, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $101.34 | 2024-2025 | Iclusig, Fruzaqla |
| Eisai INC. | $90.10 | 2024-2025 | |
| Abbvie INC. | $88.46 | 2025 | |
| Glaxosmithkline, LLC. | $87.81 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $81.58 | 2024-2025 | |
| Exelixis INC. | $80.23 | 2024-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $74.92 | 2024-2025 | Onivyde, Somatuline Depot |
| Incyte Corporation | $66.87 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Array Biopharma INC | $57.01 | 2025 | Mektovi, Lorbrena, Braftovi |
| Beone Medicines USA, INC. | $54.84 | 2025 | Brukinsa |
| Sobi, INC | $53.14 | 2025 | |
| Taiho Oncology, INC. | $48.18 | 2024-2025 | |
| Kite Pharma, INC. | $40.17 | 2024-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $20.51 | 2025 | |
| Stemline Therapeutics INC. | $20.44 | 2025 | Orserdu |
| Geron Corporation | $20.41 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $20.06 | 2024 | Qinlock, Tgct |
| Emd Serono, INC. | $19.26 | 2025 | |
| Pharmaessentia USA Corporation | $19.12 | 2025 | Besremi |
| Beigene USA, INC. | $18.94 | 2024 | Brukinsa |
| Lilly USA, LLC | $17.85 | 2025 | Verzenio, Jaypirca |
| Recordati_rare_diseases_inc. | $16.54 | 2025 | Sylvant |
| Aveo Pharmaceuticals, INC. | $16.51 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.86 | 2025 | Danziten |
| Adc Therapeutics America, INC. | $15.74 | 2025 | |
| Acrotech Biopharma INC. | $15.20 | 2025 | Beleodaq |
| Pharmacosmos Therapeutics INC. | $14.28 | 2024 | Cosela |
| Apellis Pharmaceuticals, INC. | $13.17 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.